PPPeter Paßlack

Peter Paßlack

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter Paßlack has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Merk

    Department of Pharmacy Ludwig‐Maximilians‐Universität München Munich Germany

    2 shared publications
  • Ghazaleh Tabatabai

    Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany

    2 shared publications
  • Hanna Gött

    Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany

    2 shared publications
  • Jens Schittenhelm

    Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany

    2 shared publications
  • Jonas Tellermann

    Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany

    2 shared publications
  • Marcos Tatagiba

    Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, Tübingen, Germany

    2 shared publications

Latest Publications

  • Open Access

    The superior prognostic role of pRB1 over p16 immunohistochemistry as a biomarker in meningiomas

    by Hanna Gött, Jonas Tellermann, Hannes Becker, Christina Fodi, Peter Paßlack, Elgin Hoffmann, Maria Elisa Di Francesco, Daniel J. Merk, Jürgen Honegger, Ghazaleh Tabatabai, et al.

    Background: Despite best clinical management, patients with meningiomas frequently experience tumor recurrence. During recent decades, efforts have been made to improve the prognostic stratification of meningiomas by incorporating molecular data. A subgroup of tumors harboring a homozygous CDKN2A deletion was identified, and a higher risk of tumor progression was observed, suggesting the potential use of cyclin-dependent kinases as biomarkers. Material and methods: In this retrospective single-center study, the immunohistochemical staining for the cyclin-dependent kinases p16, phosphoRB1 (pRB1), CDK4 and CDK6 was analyzed in 1751 paraffin-embedded meningioma samples. For the assessment of p16, CDK4 and CDK6, a semi-quantitative score was applied, whereas an automated quantification tool was used for pRB1. The distribution and association with histopathological results, clinical data and progression-free survival (PFS)—defined by radiographic tumor recurrence—were assessed. Results: Of all meningioma samples, 14.9% ( n = 261) expressed p16. Elevated pRB1 levels were found in 34.5% ( n = 589) of tumor samples. CDK4 and CDK6 positive staining was observed in 41.9% and 42.2% of cases, respectively. Dichotomous stratification of meningiomas based on p16 and pRB1 expression levels suggested a significant influence on PFS in univariate analyses. Multivariate analysis determined elevated pRB1 expression, WHO grading, extent of resection, adjuvant radiotherapy, male gender, NF2-status and an elevated MIB1 index as independent prognostic factors. Conclusions: High expression of pRB1 is an independent prognostic factor for shorter PFS. The prognostic impact of p16 is mostly attributed to the confounding increase of pRB1 expression.

  • Open Access

    DNA methylation profiling identifies long-range epigenetic silencing of clustered protocadherins as a key determinant of meningioma progression

    by Daniel J. Merk, Peter Paßlack, Surender Surender, Foteini Tsiami, Lara A. Haeusser, Vanessa Arnold, Vijayasarathy Sampath-Kumar, Lisa Sevenich, Andrea D. Maier, Tiit Mathiesen, et al.

    Meningioma is the most common primary brain tumour in adults. However, molecular drivers of progression occurring in a subset of meningiomas are poorly understood. We hypothesise that epigenomic variations are causal for the clinical heterogeneity of meningiomas and may be functionally relevant for disease progression. To test this hypothesis, we perform global DNA methylation profiling of a large cross-sectional cohort and a longitudinal cohort of human meningiomas. Our analysis identifies a DNA hypermethylation signature that is correlated with clinical outcomes and enables more accurate prognostication for meningiomas than previous classification systems. Analyses of longitudinal high-grade meningioma samples in comparison to clinically benign meningiomas and normal meningeal tissue show convergent contributions but differing plasticity of copy number variations and DNA hypermethylation along the trajectory of meningioma progression. Systematic analysis of DNA hypermethylation in high-grade meningiomas unravels a tumour suppressive role of clustered protocadherins by restricting β-catenin nuclear localisation, consistent with the association between nuclear β-catenin staining and meningioma progression. Together, our study provides fundamental insights into the molecular mechanisms underlying the heterogeneity of clinically benign and aggressive meningiomas and the microevolutionary adaptation during disease progression.